Immunohistochemical evaluation of O6-methylguanine DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma

Temozolomide (TMZ) is an oral alkylating agent which is widely used in the treatment of glioblastoma (GBM) and is composed of astrocytic and/or oligodendroglial tumors, and the evaluation of O6‐methylguanine DNA methyltransferase (MGMT) expression is important to predict the response to TMZ therapy....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neuropathology 2014-06, Vol.34 (3), p.268-276
Hauptverfasser:	Miyazaki, Masaya, Nishihara, Hiroshi, Terasaka, Shunsuke, Kobayashi, Hiroyuki, Yamaguchi, Shigeru, Ito, Tamio, Kamoshima, Yuuta, Fujimoto, Shin, Kaneko, Sadao, Katoh, Masahito, Ishii, Nobuaki, Mohri, Hiromi, Tanino, Mishie, Kimura, Taichi, Tanaka, Shinya
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Biomarkers, Tumor - biosynthesis Brain Neoplasms - enzymology Brain Neoplasms - mortality Brain Neoplasms - pathology Deoxyribonucleic acid DNA Female Gene Expression Regulation, Neoplastic glioblastoma Glioblastoma - enzymology Glioblastoma - mortality Glioblastoma - pathology Humans immunohistochemistry Male MGMT Middle Aged Multivariate analysis O-Methylguanine-DNA Methyltransferase - analysis O-Methylguanine-DNA Methyltransferase - biosynthesis Survival analysis Survival Rate - trends temozolomide
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!